• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

1117PDPembrolizumab and radiotherapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with contraindication to cisplatin therapy
ConclusionsThis is the first study to report acute toxicities of combining pembrolizumab with radiation in LA-HNSCC. Pembrolizumab does not potentiate typical XRT associated toxicities and no unexpected immune related adverse events were observed. Further, lower rates of feeding tube placement and grade 3/4 dermatitis, xerostomia, and mucositis were noted when compared to RTOG1016 (concurrent XRT with cisplatin or cetuximab in LA-HNSCC).Clinical trial identificationNCT02609503.Legal entity responsible for the studyThe authors.FundingMerck Sharp& Dohme Corp.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research

Auditory function and quality of life in patients receiving cisplatin chemotherapy in head and neck cancer: A case series follow-up study
Conclusion: The studies have shown hearing loss in higher frequencies, but in our study, we have observed hearing loss at speech frequency in 22.2% of patients receiving cisplatin, who also had low serum albumin levels. Periodic audiometric monitoring and serum albumin level may be helpful to provide timely intervention to prevent further hearing loss and deterioration in the quality of life.
Source: Journal of Cancer Research and Therapeutics - September 7, 2018 Category: Cancer & Oncology Authors: Balamurali Kalyanam N Sarala SM Azeem Mohiyuddin Ravi Diwakar Source Type: research

Clear Cell Variant Squamous Cell Carcinoma of Temporal Bone: Case Report and Literature Review
ConclusionThis case showed a very destructive and bizarre clinical presentation but more report of cases is needed to have a better characterization of the clinical presentation and prognosis of this variant of SCC of temporal bone.
Source: International Journal of Surgery Case Reports - September 2, 2018 Category: Surgery Source Type: research

Eagle Syndrome Secondary to Osteoradionecrosis of the Styloid Process.
CONCLUSION: Radiation is a common component of treatment for head and neck cancers. The diagnosis of Eagle syndrome secondary to osteoradionecrosis of the styloid process is an elusive, but important, diagnosis to consider because the condition can be treated successfully. PMID: 28638295 [PubMed - in process]
Source: Ochsner Journal - June 24, 2017 Category: General Medicine Tags: Ochsner J Source Type: research

Benefits, pitfalls and risks of phytotherapy in clinical practice in otorhinolaryngology
Conclusion Scientific proof of the benefit of phytotherapy in otorhinolaryngology remains to be established but, given its widespread use and the reported data, knowledge of this form of treatment needs to be developed.
Source: European Annals of Otorhinolaryngology, Head and Neck Diseases - November 30, 2016 Category: ENT & OMF Source Type: research

Nasopharyngeal carcinoma with metastases to colon
Publication date: Available online 21 February 2015 Source:Egyptian Journal of Ear, Nose, Throat and Allied Sciences Author(s): Yatiee Swany Lahuri , Irfan Mohamad , Hasmah Hashim Squamous cell carcinoma (SCC) of the nasopharynx is amongst the most common head and neck cancers. The most common distant metastases are to the bone, liver and lung. Herein, we are reporting a rare case of a 61-year-old man with nasopharyngeal carcinoma (NPC) who presented with 3weeks history of blood streaked sputum, post nasal drip and blocked nose with no history of epistaxis, tinnitus and unilateral hearing loss. Almost 2years upon complet...
Source: Egyptian Journal of Ear, Nose, Throat and Allied Sciences - March 1, 2015 Category: ENT & OMF Source Type: research

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
Conclusion: MK-2206 plus carboplatin and paclitaxel, docetaxel, or erlotinib was well-tolerated, with early evidence of antitumor activity.Trial registrationClinicalTrials.gov: NCT00848718.
Source: Journal of Hematology and Oncology - January 3, 2014 Category: Hematology Authors: L MolifeLi YanJoanna Vitfell-RasmussenAdriane ZernheltDaniel SullivanPhilippe CassierEric ChenAndrea BiondoErnestina TettehLillian SiuAmita PatnaikKyriakos PapadopoulosJohann de BonoAnthony TolcherSusan Minton Source Type: research